Company profile: TreeFrog Therapeutics
1.1 - Company Overview
Company description
- Provider of a proprietary end-to-end 3D scalable stem cell technology platform to secure cell production and quality, fasten clinical development, facilitate market access, and reduce treatment costs.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TreeFrog Therapeutics
CO.DON
HQ: Germany
Website
- Description: Provider of autologous cell therapies and cell cultivation for regenerative treatment of articular cartilage and spinal disc defects worldwide, developing, producing, and marketing minimally invasive solutions to repair knee joint cartilage damage from traumatic or degenerative defects, including matrix-associated autologous chondrocyte transplantation (M-ACT).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CO.DON company profile →
Aurion Biotech
HQ: United States
Website
- Description: Provider of clinical-stage cell therapies to treat ocular diseases, developing a platform targeting leading forms of blindness. Based in Seattle, Boston and Tokyo, candidates include Vyznova, a cell therapy for corneal endothelial cell dystrophies using cultured cells from a single donor, and AURN001, a combination cell therapy for corneal edema involving intracameral injection of neltependocel and Y-27632.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurion Biotech company profile →
Sana
HQ: United States
Website
- Description: Provider of engineered cell medicines, offering in vivo and ex vivo cell engineering platforms and hypoimmune allogeneic CAR T therapies using modified healthy donor T cells to evade immune rejection. Pipeline includes SC291 (CD19) for B-cell malignancies and severe B-cell autoimmune diseases, and SC262 (CD22) for B-cell malignancies, all in Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sana company profile →
Emmaus Medical
HQ: United States
Website
- Description: Provider of pharmaceutical therapies for rare diseases, including Endari, a prescription-grade L-glutamine oral powder to reduce acute complications of sickle cell disease in adults and children five years and older, and NutreStore (L-glutamine) for short bowel syndrome. Offers a full-service telehealth platform for Endari prescribing, dispensing and delivery, and is developing KM10544, a novel IRAK4 inhibitor for cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emmaus Medical company profile →
ArsenalBio
HQ: United States
Website
- Description: Provider of programmable CAR T-cell therapies for solid tumors, using synthetic biology to engineer T cells, including AB-1015 for ovarian cancer with dual antigen-sensing logic gating, AB-2100 for kidney cancer with potency enhancements, and the AB-3000 series for prostate cancer; collaborates with Bristol Myers Squibb and Genentech to advance next-generation T-cell therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArsenalBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TreeFrog Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TreeFrog Therapeutics
2.2 - Growth funds investing in similar companies to TreeFrog Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TreeFrog Therapeutics
4.2 - Public trading comparable groups for TreeFrog Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →